Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Vasculitis 1Neoplasms 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Glomerulonephritis 1Colorectal Neoplasms 1Colonic Neoplasms 1COVID-19 1Adenomatous Polyposis Coli 1

Interventions

Etanercept 2sotrovimab 1ciclesonide 1Tomography, X-Ray Computed 1Tomography, Emission-Computed 1Positron-Emission Tomography 1Niclosamide 1Magnetic Resonance Imaging 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vasculitis × Niclosamide × Clear all
NCT04870333 2025-06-20

PROTECT-V

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Completed
2,240 enrolled

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡